Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM

Findings from the primary endpoint supported by consistency of all secondary outcome measures assessing cognition and function TRAILBLAZER-ALZ is the first study to screen and enroll patients based on their tau pathology Biomarker results suggest potential for long-term disease modification